Rapid interrogation of cancer cell of origin through CRISPR editing
暂无分享,去创建一个
B. Carver | C. Sawyers | E. de Stanchina | M. Jasin | Weiran Feng | Hanzhi Luo | Rodrigo Romero | Qiao Wang | Teng Han | Young Sun Lee | Chao Wu | Z. Cao | Danielle Choi | Huiyong Zhao | P. Lim | HuiYong Zhao | Ninghui Mao | Aura C. Agudelo Rivera | Qiao Wang
[1] Luonan Chen,et al. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips , 2020, Nature Genetics.
[2] M. Loda,et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors , 2020, bioRxiv.
[3] C. Gersbach,et al. Immunity to Cas9 as an Obstacle to Persistent Genome Editing. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Amanda R. Kulick,et al. Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. , 2020, Cancer discovery.
[5] D. Pe’er,et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis , 2020, Science.
[6] Luke Riggan,et al. CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells. , 2020, Cell reports.
[7] N. Hosoe,et al. Chromosome Engineering of Human Colon-Derived Organoids to Develop a Model of Traditional Serrated Adenoma. , 2020, Gastroenterology.
[8] H. Hieronymus,et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes , 2019, Molecular Cancer Therapeutics.
[9] C. Don,et al. Erratum: Human embryonic stem cell–derived cardiomyocytes restore function in infarcted hearts of non-human primates , 2018, Nature Biotechnology.
[10] Jack Cuzick,et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death , 2018, eLife.
[11] Emma M Schatoff,et al. Optimized base editors enable efficient editing in cells, organoids and mice , 2018, Nature Biotechnology.
[12] J. Wilkinson,et al. A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. , 2018, Cancer cell.
[13] Hans Clevers,et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance , 2017, Nature Methods.
[14] H. Hieronymus,et al. Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis , 2017, Nature Communications.
[15] M. Rubin,et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.
[16] M. Tomishima,et al. CRISPR-Cas9–guided oncogenic chromosomal translocations with conditional fusion protein expression in human mesenchymal cells , 2017, Proceedings of the National Academy of Sciences.
[17] Francisco J. Sánchez-Rivera,et al. In vivo genome editing and organoid transplantation models of colorectal cancer , 2017, Nature Biotechnology.
[18] A. Bhardwaj,et al. In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.
[19] Jos Jonkers,et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland , 2016, Genes & development.
[20] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[21] C. Barbas,et al. Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells , 2015, Nature Protocols.
[22] Zhiping Weng,et al. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.
[23] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[24] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[25] Steven Lin,et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.
[26] J. Keith Joung,et al. Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.
[27] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[28] Joana A. Vidigal,et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system , 2014, Nature.
[29] Francisco J. Sánchez-Rivera,et al. Rapid modeling of cooperating genetic events in cancer through somatic genome editing , 2014, Nature.
[30] E. Cuppen,et al. Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.
[31] Hans Clevers,et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.
[32] Robert Langer,et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.
[33] Neville E. Sanjana,et al. Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.
[34] Daesik Kim,et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.
[35] Matthew Meyerson,et al. Targeted genomic rearrangements using CRISPR/Cas technology , 2014, Nature Communications.
[36] Luke A. Gilbert,et al. Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2013, Cell.
[37] D. Zheng,et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.
[38] M. Ittmann,et al. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. , 2012, Cancer cell.
[39] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[40] M. Shen,et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.
[41] O. Witte,et al. Isolation and functional characterization of murine prostate stem cells , 2007, Proceedings of the National Academy of Sciences.
[42] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[43] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[44] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[45] P. Leder,et al. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.
[46] H. Clevers,et al. CRISPR-Induced TMPRSS2-ERG Gene Fusions in Mouse Prostate Organoids. , 2017, JSM biotechnology & biomedical engineering.